IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Preclinical biotech developing single-course gene editing therapies for cardiovascular disease.
Industry: Health Care
Latest Trade: $6.64 0.00 (0.0%)
First Day Return: +68.0%
Return from IPO: -65.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 05/28/2021 |
Offer Price | $19.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 14.0 |
Deal Size ($mm) | $267 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/16/2021 |
Offer Price | $19.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 14.0 |
Deal Size ($mm) | $267 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2018 |
Employees | 63 |
Website www.vervetx.com |